We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors

This study has been terminated.
(Poor enrollment)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00746603
First Posted: September 4, 2008
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Children's Hospital of Philadelphia
Information provided by (Responsible Party):
Columbia University
  Purpose

Lay abstract: Study Purpose With contemporary combined modality therapy the expected longterm survival of children and adolescents with Hodgkin's disease (HD) is exceedingly high. Thus, the emphasis for future therapeutic interventions must include attention to the late effects of therapy. The development of cardiovascular disease as a late effect of radiation therapy has been well described and documented. Our recent pilot study of child and young adult HD survivors revealed significant subclinical atherosclerosis as evidenced by increased Carotid Artery Intima Media Thickness (CIMT) compared to controls. The higher CIMT values were positively associated with increasing age, total cholesterol, LDLcholesterol and diastolic BP. This finding was present in children and young adults who had received no or low dose radiation suggesting that chemotherapy or the disease process itself contributes to the development of atherosclerosis and risk for cardiovascular disease. Numerous studies have shown HMG CoA reductase inhibitors ("statins") to be effective in reducing the progression of atherosclerosis in adults. These agents have been studied in children and young adults for over a decade.

The primary aim of this study is:

To obtain pilot safety data on the use of simvastatin in young adults treated for HD.

The secondary aims of this study are:

To obtain pilot data on the effect of simvastatin on subclinical carotid artery atherosclerosis as measured by Carotid Artery IMT in young adults treated for HD.

To obtain pilot data on the effect of simvastatin on markers of inflammation measured in the serum of young adults treated for HD.

To obtain pilot data to serve as the basis for the development of a multicenter randomized study for the use of simvastatin in survivors of HD.


Condition Intervention
Carotid Artery Disease Drug: Simvastatin

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Feasibility Study to Evaluate the Safety of Simvastatin in Young Adults Treated for Hodgkin's Disease

Resource links provided by NLM:


Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Liver Function Tests and Creatine Kinase [ Time Frame: every 4 weeks x 3, then at 26 weeks ]

Secondary Outcome Measures:
  • Carotid Artery Intima Media Thickness [ Time Frame: 26 weeks ]

Enrollment: 18
Study Start Date: January 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Escalating dose of simvastatin
Drug: Simvastatin
All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least three years from completion of treatment for Hodgkin's Disease
  • Age 18- 35
  • Ability to complete self report questionnaires in either English or Spanish
  • Willingness of patient, or parent/guardian if patient less than 18 years of age to sign consent to participate in study
  • Willingness of patient to sign assent if greater than 7 years of age and less than 18 years

Exclusion Criteria:

  • Pregnant or breast feeding
  • Tanner Stage 1
  • Currently taking cyclosporine, niacin, antiretrovirals, macrolide antibiotic, azole antifungal
  • Liver enzymes greater than 1.5 times the upper level of normal
  • Creatine Kinase greater than 2 times the upper level of normal
  • Use of estrogen containing contraceptive
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00746603


Locations
United States, New York
Columbia Univeristy Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Children's Hospital of Philadelphia
Investigators
Principal Investigator: Jennifer Levine, MD Columbia Univeristy Medical Center
  More Information

Responsible Party: Columbia University
ClinicalTrials.gov Identifier: NCT00746603     History of Changes
Other Study ID Numbers: AAAB4447
First Submitted: September 2, 2008
First Posted: September 4, 2008
Last Update Posted: October 12, 2017
Last Verified: July 2013

Additional relevant MeSH terms:
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Simvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors